Prostate Cancer Study
The Prostate Cancer Medically Optimized Genome-Enhanced Therapy (PROMOTE) study uses genetic clues in castration-resistant prostate cancer that may identify an individualized treatment approach for men with the disease.
Understanding the molecular biology behind castration-resistant prostate cancer has led to more treatment options, but there are still no definite conclusions about which specific drug best treats patients — maximum suppression of cancer growth while minimizing side effects.
The PROMOTE study explores the genetic characteristics of each tumor to predict these treatment paradigms for the future, resulting in more effective and less toxic options for patients.
Our long-term goal is to improve treatments for men with advanced prostate cancer by using genomic sequencing to increase life span and quality of life. We also will uncover novel vulnerable targets in the cancer genome that may provide new drug therapies.
Eligible participants are men:
- With castration-resistant prostate cancer or prostate cancer not responding to hormone treatments
- About to begin abiraterone acetate therapy
- Agreeable to undergoing two tumor biopsies
During the study, participants travel to Mayo Clinic for an initial biopsy (before beginning abiraterone acetate) and a second biopsy approximately three months later. The cell tissue collected is analyzed to identify gene alterations in the tumor that could eventually be targeted with treatments. Tissue is preserved for future research.
Participants can continue to be treated by their local cancer care team during this period and beyond. In addition, the Mayo team carefully monitors participants' cancer via follow-up studies and the genetic signature of tumors that were biopsied so that patients may benefit from future treatments.
Collaborators who refer 10 or more study patients will be given academic credit in the form of co-authorship on scientific publications and potential access to specimens (arranged on a case-by-case basis and driven by the scientific merit of the proposals).
We expect molecular signatures to take several years to create. During that time, research information is shared for patient benefit.
Patients, referring physicians and research collaborators can contact our PROMOTE study coordinators:
- Elizabeth A. Scheel
- Phone: 507-284-3067
- Email: firstname.lastname@example.org
- Jill K. Burton
- Phone: 507-284-8440
- Email: email@example.com
You can also contact the Center for Individualized Medicine for information on other studies and trials.
Support this study
Generous donors, sponsors and benefactors make this study possible. Your gift supports research to apply the principles of individualized medicine to improve the standard of care for men with prostate cancer.
Gifts are needed in several key areas for the PROMOTE study:
Biopsy and travel costs. Study participants travel to Mayo Clinic at least twice for necessary blood work and biopsies. The study protocol requires each participant to have two biopsies, which is unique in this stage of the disease. Biopsies may occur anywhere the cancer has spread, including the bones, lymph nodes or liver — and may not be covered by insurance. Some participants make additional trips to Mayo for initial consultations.
Mayo assumes responsibility for all costs associated with biopsies and travel, rather than passing on these expenses to study participants. There are 200 participants needed in the first phase of the study, representing a significant expense.
- Team and equipment costs. The PROMOTE study team relies on collaboration from laboratory services, clinicians, researchers, genomic experts and many others.